Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases

Yang, Ji-Yeon; Zhang, Lixiao; Yu, Caijia; Yang, Xiaofeng; Wang, Hong

doi:10.1186/2050-7771-2-1

Cited by 838 publications

(818 citation statements)

References 62 publications

Supporting

Mentioning

772

Contrasting

Unclassified

Order By: Relevance

“…The intermediate monocytes were associated previously with a proinflammatory role, being high producers of IL-1β and TNF in response to lipopolysaccharide (LPS), but low producers of reactive oxygen species (ROS), although showing high phagocytic ability [23]. It was suggested that intermediate monocytes are probably involved in antigen presentation and T cell activation [20]. An increase in the CD14…”

Section: Cd16mentioning

confidence: 99%

“…S1). As described in the literature [20,21], we considered three monocyte subpopulations, one with high expression of CD14 and low or no expression of CD16 (CD14 (Fig. 2).…”

Section: + Peripheral Blood Monocytesmentioning

confidence: 99%

“…Peripheral blood monocytes have been divided into three distinct subsets according to CD14 and CD16 marker expression [18,20,21] + monocyte subsets, particularly the intermediate subset, have been associated with inflammatory functions [20] and are known to be the major producers of inflammatory cytokines such as TNF and interleukin (IL)-1β [22,23]. It was reported that, in CD patients with active disease, CD16…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Infliximab therapy increases the frequency of circulating CD16+ monocytes and modifies macrophage cytokine response to bacterial infection

Nazareth

Magro

Silva

et al. 2014

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryCrohn's disease (CD) has been correlated with altered macrophage response to microorganisms. Considering the efficacy of infliximab treatment on CD remission, we investigated infliximab effects on circulating monocyte subsets and on macrophage cytokine response to bacteria. Human peripheral blood monocyte-derived macrophages were obtained from CD patients, treated or not with infliximab. Macrophages were infected with Escherichia coli, Enterococcus faecalis, Mycobacterium avium subsp. paratuberculosis (MAP) or M. avium subsp avium, and cytokine levels [tumour necrosis factor (TNF) and interleukin (IL)-10] were evaluated at different time-points. To evaluate infliximab-dependent effects on monocyte subsets, we studied CD14 and CD16 expression by peripheral blood monocytes before and after different infliximab administrations. We also investigated TNF secretion by macrophages obtained from CD16 + and CD16 − monocytes and the frequency of TNF + cells among CD16 + and CD16 − monocyte-derived macrophages from CD patients. Infliximab treatment resulted in elevated TNF and IL-10 macrophage response to bacteria. An infliximab-dependent increase in the frequency of circulating CD16 + monocytes (particularly the CD14 ++ CD16 + subset) was also observed (before infliximab: 4·65 ± 0·58%; after three administrations: 10·68 ± 2·23%). In response to MAP infection, macrophages obtained from CD16 + monocytes were higher TNF producers and CD16 + macrophages from infliximab-treated CD patients showed increased frequency of TNF + cells. In conclusion, infliximab treatment increased the TNF production of CD macrophages in response to bacteria, which seemed to depend upon enrichment of CD16 + circulating monocytes, particularly of the CD14 ++ CD16 + subset. Infliximab treatment of CD patients also resulted in increased macrophage IL-10 production in response to bacteria, suggesting an infliximab-induced shift to M2 macrophages.

show abstract

Section: Cd16mentioning

confidence: 99%

“…S1). As described in the literature [20,21], we considered three monocyte subpopulations, one with high expression of CD14 and low or no expression of CD16 (CD14 (Fig. 2).…”

Section: + Peripheral Blood Monocytesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Infliximab therapy increases the frequency of circulating CD16+ monocytes and modifies macrophage cytokine response to bacterial infection

Nazareth

Magro

Silva

et al. 2014

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Recently, it was suggested that PBM may be used after appropriate loading with contrast agents or other markers to visualize AS plaques non-invasively [40]. In early lesions the M2 phenotype predominates, whereas during AS development the frequency of M1 phenotype increases [38].…”

Section: The Biology Of Monocytes and Macrophagesmentioning

confidence: 99%

Nanoparticle uptake by macrophages in vulnerable plaques for atherosclerosis diagnosis

Melzer

Ankri

Fixler

et al. 2015

Journal of Biophotonics

View full text Add to dashboard Cite

The composition of atherosclerotic (AS) plaques is crucial concerning rupture, thrombosis and clinical events. Two plaque types are distinguished: stable and vulnerable plaques. Vulnerable plaques are rich in inflammatory cells, mostly only M1 macrophages, and are highly susceptible to rupture. These plaques represent a high risk particularly with the standard invasive diagnosis by coronary angiography. So far there are no non‐invasive low‐risk clinical approaches available to detect and distinguish AS plaque types in vivo. The perspective review introduces a whole work‐flow for a novel approach for non‐invasive detection and classification of AS plaques using the diffusion reflection method with gold nanoparticle loaded macrophages in combination with flow and image cytometric analysis for quality assurance. Classical biophotonic methods for AS diagnosis are summarized. Phenotyping of monocytes and macrophages are discussed for specific subset labelling by nanomaterials, as well as existing studies and first experimental proofs of concept for the novel approach are shown.

show abstract

“…In response to inflammatory stimuli (i.e., LPS), the classical monocytes are selectively trafficked, in first instance, to the sites of inflammation, producing pro-inflammatory cytokines and contributing to local and systemic inflammation (Yang et al, 2014). These monocytes are highly infiltrative and can be differentiated into inflammatory macrophages, M1 acting in the acute phase of inflammation.…”

mentioning

confidence: 99%

Pharmacological effects of mitraphylline from Uncaria tomentosa in primary human monocytes: Skew toward M2 macrophages

Paz

Puerta

Fernández-Arche

et al. 2015

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Ethnopharmacological relevanceUncaria tomentosa (Willdenow ex Roemer & Schultes) DC. (Rubiaceae) is a Peruvian thorny liana, commonly known as "cat's claw", and traditionally used in folk medicine to deal with several inflammatory diseases. Mitraphylline (MTP) is the most abundant pentacyclic oxindolic alkaloid (POA) from U.Tomentosa and has been reported to modify the inflammatory response. Herein, we have sought to identify the mechanisms underlying this modulatory effect of MTP on primary human monocytes and its ability to regulate differentiation processes on human primary monocyte and monocyte-derived macrophages. Material and methodsIn vitro studies with human primary monocytes and monocyte-derived macrophages were performed. Monocytes and M0 macrophages were exposed to MTP (25 µM) and LPS (100 ng/mL). M0 macrophages were polarized to M1 and M2 phenotypes in the absence or presence of MTP. The activation state of monocytes/macrophages was assessed by flow cytometry, gene expression and protein analysis of different specific markers. ResultsIn human primary monocytes, the incubation of MTP for 24 h reduced the number of classical (CD14++CD16-) and intermediated (CD14++CD16+) subsets when compared to untreated or LPS-treated cells. MTP also reduced the chemotactic capacity of human primary monocytes.In addition, MTP promoted the polarization of M0 macrophages toward an anti-inflammatory M2 phenotype, the abrogation of the release of pro-inflammatory cytokines such as TNFα, IL-6 or IL-1β, as well as the restoration of markers for M2 macrophages in LPS-treated M1 macrophages. 3 ConclusionsOur results suggest that MTP may be a key modulator for regulating the plasticity of monocytes/macrophages and the attenuation of the inflammatory response. Mitraphylline (Pubchem CID: 94160) Chemical compounds studied in this article

show abstract

Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases

Cited by 838 publications

References 62 publications

Infliximab therapy increases the frequency of circulating CD16+ monocytes and modifies macrophage cytokine response to bacterial infection

Infliximab therapy increases the frequency of circulating CD16+ monocytes and modifies macrophage cytokine response to bacterial infection

Nanoparticle uptake by macrophages in vulnerable plaques for atherosclerosis diagnosis

Pharmacological effects of mitraphylline from Uncaria tomentosa in primary human monocytes: Skew toward M2 macrophages

Contact Info

Product

Resources

About